The study provided proof-of-concept in using an antisense oligonucleotide (ASO) against PNPLA3-I148M to ameliorate hepatic steatosis and NASH development and is currently in clinical trials (NCT04142424, NCT04483947) for patients who are homozygous for the variant [302]. This evidence concerns the gene PNPLA3 and fatty liver disease.